The Microbiome and the Respiratory Tract

Annual Review of Physiology

Volumn 78, Issue , 2016, Pages 481-504

  Dickson, Robert P ^a   Erb Downward, John R ^a   Martinez, Fernando J ^b   Huffnagle, Gary B ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

16S rRNA; Culture independent; Lung; Microbial ecology; Microbiota; Pulmonary

Indexed keywords

ASTHMA; BACTERIUM CONTAMINATION; BRONCHIECTASIS; CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; DYSBIOSIS; ECOLOGY; ECOSYSTEM; FIBROSING ALVEOLITIS; HUMAN; LUNG TRANSPLANTATION; MICROBIAL COMMUNITY; MICROBIAL IDENTIFICATION; MICROBIOME; OROPHARYNX; PNEUMONIA; POPULATION DYNAMICS; PRIORITY JOURNAL; RESPIRATORY SYSTEM; REVIEW; TOPOGRAPHY; UPPER RESPIRATORY TRACT; ANIMAL; LUNG DISEASE; MICROBIOLOGY; MICROFLORA; PHYSIOLOGY;

ANIMALS; HUMANS; LUNG DISEASES; MICROBIOTA; RESPIRATORY SYSTEM;

EID: 84958635963     PISSN: 00664278     EISSN: 15451585     Source Type: Book Series    
DOI: 10.1146/annurev-physiol-021115-105238     Document Type: Review

References (135)

1. Lederberg J. 2001. 'Ome sweet 'omics-A genealogical treasury of words. The Scientist, April 2
2. Cotran RS, Kumar V, Collins T, Robbins SL. 1999. Robbins Pathologic Basis of Disease. Philadelphia: Saunders
3. Horikoshi K,Grant WD. 1998. Extremophiles: Microbial Life in Extreme Environments.New York:Wiley-Liss
4. Hilty M, Burke C, Pedro H, Cardenas P, Bush A, et al. 2010. Disordered microbial communities in asthmatic airways. PLOS ONE 5:e8578
5. Pasteur L. 1860. Expériences relatives aux générations dites spontanées. C. R. Hebd. Séances Acad. Sci. D 50:303-7
6. Hildebrandt G. 1888. Experimentelle Untersuchungen über das Eindringen pathogener Mikroorganismen von den Luftwegen und der Lunge aus. Beitr. Pathol. Anat. Physiol. 3:411-50
7. Dürck H. 1897. Studien über die Ätiologie und Histologie der Pneumonie im Kindesalter und der Pneumonie im Allgemeinen. Deutsch. Arch. klin. Med. 58:368
8. QuenselU. 1902. Untersuchungen über das Vorkommen von Bakterien in den Lungen und bronchialen Lymphdrüsen gesunder Thiere. Z. Hyg. Infect. 40:505-21
9. Jones FS. 1922. The source of themicroorganisms in the lungs of normal animals. J. Exp. Med. 36:317-28
10. Thomson SC, Hewlett RT. 1896. The fate of micro-organisms in inspired air. Lancet 147:86-87
11. Quinn LH, Meyer OO. 1929. The relationship of sinusitis and bronchiectasis. Arch. Otolaryngol. 10:152-65
12. Dickson RP, Erb-Downward JR, Prescott HC, Martinez FJ, Curtis JL, et al. 2014. Analysis of culturedependent versus culture-independent techniques for identification of bacteria in clinically obtained bronchoalveolar lavage fluid. J. Clin. Microbiol. 52:3605-13
13. Dickson RP, Erb-Downward JR, Huffnagle GB. 2013. The role of the bacterial microbiome in lung disease. Expert Rev. Respir. Med. 7:245-57
14. Venkataraman A, Bassis CM, Beck JM, Young VB, Curtis JL, et al. 2015. Application of a neutral community model to assess structuring of the human lung microbiome. MBio 6:e02284-14
15. Bassis CM, Erb-Downward JR, Dickson RP, Freeman CM, Schmidt TM, et al. 2015. Analysis of the upper respiratory tract microbiotas as the source of the lung and gastricmicrobiotas in healthy individuals. MBio 6:e00037-15
16. Winslow CE. 1908. A new method of enumerating bacteria in air. Science 28:28-31
17. Gleeson K, Eggli DF, Maxwell SL. 1997. Quantitative aspiration during sleep in normal subjects. Chest 111:1266-72
18. Huxley EJ, Viroslav J, Gray WR, Pierce AK. 1978. Pharyngeal aspiration in normal adults and patients with depressed consciousness. Am. J. Med. 64:564-68
19. Amberson JB. 1954. A clinical consideration of abscesses and cavities of the lung. Bull. Johns Hopkins Hosp. 94:227-37
20. Dickson RP, Erb-Downward JR, Huffnagle GB. 2014. Towards an ecology of the lung: new conceptual models of pulmonary microbiology and pneumonia pathogenesis. Lancet Respir. Med. 2:238-46
21. Dickson JL, Head JW, Levy JS, Marchant DR. 2013. Don Juan Pond, Antarctica: near-surface CaCl2-brine feeding Earth's most saline lake and implications for Mars. Sci. Rep. 3:1166
22. Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, BruceKD. 2004. Characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16S ribosomal DNA terminal restriction fragment length polymorphism profiling. J. Clin. Microbiol. 42:5176-83
23. Rogers GB, Hart CA, Mason JR, Hughes M, Walshaw MJ, Bruce KD. 2003. Bacterial diversity in cases of lung infection in cystic fibrosis patients: 16S ribosomal DNA (rDNA) length heterogeneity PCR and 16S rDNA terminal restriction fragment length polymorphism profiling. J. Clin. Microbiol. 41:3548-58
24. Hamady M, Knight R. 2009. Microbial community profiling for human microbiome projects: tools, techniques, and challenges. Genome Res. 19:1141-52
25. Salter SJ, Cox MJ, Turek EM, Calus ST, Cookson WO, et al. 2014. Reagent and laboratory contamination can critically impact sequence-based microbiome analyses. BMC Biol. 12:87
26. Dickson RP, Erb-Downward JR, Prescott HC, Martinez FJ, Curtis JL, et al. 2014. Cell-associated bacteria in the human lung microbiome. Microbiome 2:28
27. Dickson RP, Erb-Downward JR, Freeman CM,Walker N, Scales BS, et al. 2014. Changes in the lung microbiome following lung transplantation include the emergence of two distinct Pseudomonas species with distinct clinical associations. PLOS ONE 9:e97214
28. Dickson RP, Martinez FJ, Huffnagle GB. 2014. The role of the microbiome in exacerbations of chronic lung diseases. Lancet 384:691-702
29. Dickson RP, Erb-Downward JR, Freeman CM, McCloskey L, Beck JM, et al. 2015. Spatial variation in the healthy human lung microbiome and the adapted island model of lung biogeography. Ann. Am. Thorac. Soc. 12:821-30
30. SegalLN, Alekseyenko AV, Clemente JC, Kulkarni R,WuB, et al. 2013. Enrichment of lung microbiome with supraglottic taxa is associated with increased pulmonary inflammation. Microbiome 1:19
31. Cox MJ, Allgaier M, Taylor B, Baek MS, Huang YJ, et al. 2010. Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients. PLOS ONE 5:e11044
32. Molyneaux PL, Mallia P, Cox MJ, Footitt J, Willis-Owen SA, et al. 2013. Outgrowth of the bacterial airwaymicrobiome after rhinovirus exacerbation of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 188:1224-31
33. Rogers GB, van der Gast CJ, Cuthbertson L, Thomson SK, Bruce KD, et al. 2013. Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition. Thorax 68:731-37
34. Zhao J, Murray S, Lipuma JJ. 2014. Modeling the impact of antibiotic exposure on human microbiota. Sci. Rep. 4:4345
35. Zhao J, Schloss PD, Kalikin LM, Carmody LA, Foster BK, et al. 2012. Decade-long bacterial community dynamics in cystic fibrosis airways. PNAS 109:5809-14
36. Rogers GB, Zain NM, Bruce KD, Burr LD, Chen AC, et al. 2014. A novel microbiota stratification system predicts future exacerbations in bronchiectasis. Ann. Am. Thorac. Soc. 11:496-503
37. Hasleton PS. 1972. The internal surface area of the adult human lung. J. Anat. 112:391-400
38. Helander HF, Fandriks L. 2014. Surface area of the digestive tract-revisited. Scand. J. Gastroenterol. 49:681-89
39. Policard J, Galy P. 1945. Les bronches: structures et mécanismes a l'état normal et pathologique. Paris:Masson &Cie
40. Wu H, Kuzmenko A, Wan S, Schaffer L, Weiss A, et al. 2003. Surfactant proteins A and D inhibit the growth of Gram-negative bacteria by increasing membrane permeability. J. Clin. Investig. 111:1589-602
41. LighthartB. 2000. Mini-review of the concentration variations found in the alfresco atmospheric bacterial populations. Aerobiologia 16:7-16
42. Munyard P, Bush A. 1996. How much coughing is normal? Arch. Dis. Child 74:531-34
43. Hatch TF. 1961. Distribution and deposition of inhaled particles in respiratory tract. Bacteriol. Rev. 25:237-40
44. Ingenito EP, Solway J, McFadden ER Jr, Pichurko B, Bowman HF, et al. 1987. Indirect assessment of mucosal surface temperatures in the airways: theory and tests. J. Appl. Physiol. 63:2075-83
45. West JB. 1978. Regional differences in the lung. Chest 74:426-37
46. MacArthur RH, Wilson EO. 1963. An equilibrium theory of insular zoogeography. Evolution 17:373-87
47. D'Ovidio F, Singer LG, Hadjiliadis D, Pierre A, Waddell TK, et al. 2005. Prevalence of gastroesophageal reflux in end-stage lung disease candidates for lung transplant. Ann. Thorac. Surg. 80:1254-60
48. Raghu G, Freudenberger TD, Yang S, Curtis JR, Spada C, et al. 2006. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur. Respir. J. 27:136-42
49. Coxson HO, Hogg JC, Mayo JR, Behzad H, Whittall KP, et al. 1997. Quantification of idiopathic pulmonary fibrosis using computed tomography and histology. Am. J. Respir. Crit. Care Med. 155:1649-56
50. Coxson HO, Rogers RM, Whittall KP, D'Yachkova Y, Pare PD, et al. 1999. A quantification of the lung surface area in emphysema using computed tomography. Am. J. Respir. Crit. Care Med. 159:851-56
51. Molyneaux PL, Cox MJ, Willis-Owen SA, Mallia P, Russell KE, et al. 2014. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis.Am. J. Respir. Crit.CareMed. 190:906-13
52. Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, et al. 2002. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J. Clin. Investig. 109:317-25
53. Schmidt A, Belaaouaj A, Bissinger R, Koller G, Malleret L, et al. 2014. Neutrophil elastase-mediated increase in airway temperature during inflammation. J. Cyst. Fibros. 13:623-31
54. Konstan MW, Hilliard KA, Norvell TM, Berger M. 1994. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am. J. Respir. Crit. Care Med. 150:448-54
55. Papi A, Bellettato CM, Braccioni F, RomagnoliM, Casolari P, et al. 2006. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am. J. Respir. Crit. Care Med. 173:1114-21
56. Soler N, Ewig S, Torres A, Filella X, Gonzalez J, Zaubet A. 1999. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur. Respir. J. 14:1015-22
57. Finlay BB, McFadden G. 2006. Anti-immunology: evasion of the host immune system by bacterial and viral pathogens. Cell 124:767-82
58. Freestone PP, HirstRA, Sandrini SM, Sharaff F, FryH, et al. 2012. Pseudomonas aeruginosa-catecholamine inotrope interactions: a contributory factor in the development of ventilator-associated pneumonia? Chest 142:1200-10
59. Kanangat S, Meduri GU, Tolley EA, Patterson DR, Meduri CU, et al. 1999. Effects of cytokines and endotoxin on the intracellular growth of bacteria. Infect. Immun. 67:2834-40
60. Kaza SK, McClean S, Callaghan M. 2011. IL-8 released from human lung epithelial cells induced by cystic fibrosis pathogens Burkholderia cepacia complex affects the growth and intracellular survival of bacteria. Int. J. Med. Microbiol. 301:26-33
61. Porat R, Clark BD, Wolff SM, Dinarello CA. 1991. Enhancement of growth of virulent strains of Escherichia coli by interleukin-1. Science 254:430-32
62. Marks LR, Davidson BA, Knight PR, Hakansson AP. 2013. Interkingdom signaling induces Streptococcus pneumoniae biofilm dispersion and transition from asymptomatic colonization to disease. MBio 4:e00438-13
63. Aagaard K, Ma J, Antony KM, Ganu R, Petrosino J, Versalovic J. 2014. The placenta harbors a unique microbiome. Sci. Transl. Med. 6:237ra65
64. DiGiulio DB. 2012. Diversity of microbes in amniotic fluid. Semin. Fetal Neonatal Med. 17:2-11
65. Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, et al. 2010. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. PNAS 107:11971-75
66. Capone KA, Dowd SE, Stamatas GN, Nikolovski J. 2011. Diversity of the human skin microbiome early in life. J. Investig. Dermatol. 131:2026-32
67. Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, et al. 2012. Human gut microbiome viewed across age and geography. Nature 486:222-27
68. Biesbroek G, Tsivtsivadze E, Sanders EA, Montijn R, Veenhoven RH, et al. 2014. Early respiratory microbiota composition determines bacterial succession patterns and respiratory health in children. Am. J. Respir. Crit. Care Med. 190:1283-92
69. Teo Shu M, Mok D, Pham K, Kusel M, SerralhaM, et al. 2015. The infant nasopharyngeal microbiome impacts severity of lower respiratory infection and risk of asthma development. Cell HostMicrobe 17:704-15
70. Morris A, Beck JM, Schloss PD, Campbell TB, Crothers K, et al. 2013. Comparison of the respiratory microbiome in healthy nonsmokers and smokers. Am. J. Respir. Crit. Care Med. 187:1067-75
71. Lozupone C, Cota-Gomez A, Palmer BE, Linderman DJ, Charlson ES, et al. 2013. Widespread colonization of the lung by Tropheryma whipplei in HIV infection. Am. J. Respir. Crit. Care Med. 187:1110-17
72. Sullivan CE,Murphy E, Kozar LF, Phillipson EA. 1978. Waking and ventilatory responses to laryngeal stimulation in sleeping dogs. J. Appl. Physiol. Respir. Environ. Exerc. Physiol. 45:681-89
73. Goddard AF, Staudinger BJ, Dowd SE, Joshi-Datar A, Wolcott RD, et al. 2012. Direct sampling of cystic fibrosis lungs indicates that DNA-based analyses of upper-airway specimens can misrepresent lung microbiota. PNAS 109:13769-74
74. Willner D, Haynes MR, Furlan M, Schmieder R, Lim YW, et al. 2012. Spatial distribution of microbial communities in the cystic fibrosis lung. ISME J. 6:471-74
75. Erb-Downward JR, Thompson DL, Han MK, Freeman CM, McCloskey L, et al. 2011. Analysis of the lung microbiome in the "healthy" smoker and in COPD. PLOS ONE 6:e16384
76. Huang YJ, Nelson CE, Brodie EL, Desantis TZ, BaekMS, et al. 2011. Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma. J. Allergy Clin. Immunol. 127:372-81.e1-3
77. Goleva E, Jackson LP, Harris JK, Robertson CE, Sutherland ER, et al. 2013. The effects of airway microbiome on corticosteroid responsiveness in asthma. Am. J. Respir. Crit. Care Med. 188:1193-201
78. Marri PR, Stern DA, Wright AL, Billheimer D, Martinez FD. 2013. Asthma-associated differences in microbial composition of induced sputum. J. Allergy Clin. Immunol. 131:346-52.e1-3
79. Slater M, Rivett DW, Williams L, Martin M, Harrison T, et al. 2013. The impact of azithromycin therapy on the airway microbiota in asthma. Thorax 69:673-74
80. Green BJ,Wiriyachaiporn S, Grainge C, Rogers GB, Kehagia V, et al. 2014. Potentially pathogenic airway bacteria and neutrophilic inflammation in treatment resistant severe asthma. PLOS ONE 9:e100645
81. Ege MJ, Mayer M, Normand AC, Genuneit J, Cookson WO, et al. 2011. Exposure to environmental microorganisms and childhood asthma. N. Engl. J. Med. 364:701-9
82. NoverrMC, Noggle RM, Toews GB, Huffnagle GB. 2004. Role of antibiotics and fungal microbiota in driving pulmonary allergic responses. Infect. Immun. 72:4996-5003
83. Trompette A, Gollwitzer ES, Yadava K, Sichelstiel AK, Sprenger N, et al. 2014. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat. Med. 20:159-66
84. Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. 2002. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 57:875-79
85. Essilfie AT, Horvat JC, Kim RY, Mayall JR, Pinkerton JW, et al. 2015. Macrolide therapy suppresses key features of experimental steroid-sensitive and steroid-insensitive asthma. Thorax 70:458-67
86. Simpson JL, Powell H, BoyleMJ, ScottRJ, Gibson PG. 2008. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am. J. Respir. Crit. Care Med. 177:148-55
87. Sze MA, Abbasi M, Hogg JC, Sin DD. 2014. A comparison between droplet digital and quantitative PCR in the analysis of bacterial 16S load in lung tissue samples from control and COPD GOLD 2. PLOS ONE 9:e110351
88. Sze MA, Utokaparch S, Elliott WM, Hogg JC, Hegele RG. 2015. Loss of GD1-positive Lactobacillus correlates with inflammation in human lungs with COPD. BMJ Open 5:e006677
89. Garcia-NunezM,Millares L, PomaresX, Ferrari R, Pérez-Brocal V, et al. 2014. Severity-related changes of bronchial microbiome in chronic obstructive pulmonary disease. J. Clin. Microbiol. 52:4217-23
90. WuD, HouC, Li Y, Zhao Z, Liu J, et al. 2014. Analysis of the bacterial community in chronic obstructive pulmonary disease sputum samples by denaturing gradient gel electrophoresis and real-time PCR. BMC Pulm. Med. 14:179
91. SzeMA, Dimitriu PA,Hayashi S, Elliott WM,McDonough JE, et al. 2012. The lung tissue microbiome in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 185:1073-80
92. Morris A, Sciurba FC, Lebedeva IP,Githaiga A, Elliott WM, et al. 2004. Association of chronic obstructive pulmonary disease severity and Pneumocystis colonization. Am. J. Respir. Crit. Care Med. 170:408-13
93. Cui L, Lucht L, Tipton L, Rogers MB, Fitch A, et al. 2015. Topographic diversity of the respiratory tract mycobiome and alteration in HIV and lung disease. Am. J. Respir. Crit. Care Med. 191:932-42
94. Bafadhel M, McKenna S, Agbetile J, Fairs A, Desai D, et al. 2014. Aspergillus fumigatus during stable state and exacerbations of COPD. Eur. Respir. J. 43:64-71
95. Cystic Fibrosis Foundation. 2014. Patient registry annual data report 2014. https://www.cff.org/2014- CFF-Annual-Data-Report-to-the-Center-Directors.pdf
96. Hurley MN, Ariff AH, BertenshawC, Bhatt J, Smyth AR. 2012. Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis. J. Cyst. Fibros. 11:288-92
97. Smith AL, Fiel SB,Mayer-Hamblett N, Ramsey B, Burns JL. 2003. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 123:1495-502
98. Gold R, Overmeyer A, Knie B, Fleming PC, Levison H. 1985. Controlled trial of ceftazidime versus ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis. Pediatr. Infect. Dis. 4:172-77
99. Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Kehagia V, et al. 2005. Bacterial activity in cystic fibrosis lung infections. Respir. Res. 6:49
100. Sibley CD, Parkins MD, Rabin HR, Duan K, Norgaard JC, Surette MG. 2008. A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients. PNAS 105:15070-75
101. Bruzzese E, Raia V, Spagnuolo MI, Volpicelli M, De Marco G, et al. 2007. Effect of Lactobacillus GG supplementation on pulmonary exacerbations in patients with cystic fibrosis: a pilot study. Clin. Nutr. 26:322-28
102. Weiss B, Bujanover Y, Yahav Y, VilozniD, Fireman E, Efrati O. 2010. Probiotic supplementation affects pulmonary exacerbations in patients with cystic fibrosis: a pilot study. Pediatr. Pulmonol. 45:536-40
103. Madan JC, Koestler DC, Stanton BA, Davidson L, Moulton LA, et al. 2012. Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: interaction between intestinal and respiratory tracts and impact of nutritional exposures. MBio 3:e00251-12
104. Carmody LA, Zhao J, Kalikin LM, LeBar W, Simon RH, et al. 2015. The daily dynamics of cystic fibrosis airway microbiota during clinical stability and at exacerbation. Microbiome 3:12
105. Zhao J, Evans CR, Carmody LA, LiPuma JJ. 2015. Impact of storage conditions on metabolite profiles of sputum samples from persons with cystic fibrosis. J. Cyst. Fibros. 14:468-73
106. MaughanH, Cunningham KS, Wang PW, Zhang Y, Cypel M, et al. 2012. Pulmonary bacterial communities in surgically resected noncystic fibrosis bronchiectasis lungs are similar to those in cystic fibrosis. Pulm. Med. 2012:746358
107. Tunney MM, Einarsson GG, Wei L, Drain M, Klem ER, et al. 2013. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am. J. Respir. Crit. Care Med. 187:1118-26
108. Taylor SL,RogersGB, Chen AC, Burr LD, McGuckin MA, Serisier DJ. 2015. Matrix metalloproteinases vary with airway microbiota composition and lung function in non-cystic fibrosis bronchiectasis. Ann. Am. Thorac. Soc. 2: 701-7
109. Young LR, Hadjiliadis D, Davis RD, Palmer SM. 2003. Lung transplantation exacerbates gastroesophageal reflux disease. Chest 124:1689-93
110. Yusen RD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, et al. 2014. The registry of the International Society forHeart and Lung Transplantation: thirty-first adult lung and heart-lung transplant report-2014; focus theme: retransplantation. J. Heart Lung Transplant. 33:1009-24
111. Botha P, Archer L, Anderson RL, Lordan J, Dark JH, et al. 2008. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation 85:771-74
112. Gottlieb J, Mattner F, Weissbrodt H, Dierich M, Fuehner T, et al. 2009. Impact of graft colonization with gram-negative bacteria after lung transplantation on the development of bronchiolitis obliterans syndrome in recipients with cystic fibrosis. Respir. Med. 103:743-49
113. Vos R, Vanaudenaerde BM, Geudens N, Dupont LJ, Van Raemdonck DE, Verleden GM. 2008. Pseudomonal airway colonisation: risk factor for bronchiolitis obliterans syndrome after lung transplantation? Eur. Respir. J. 31:1037-45
114. Borewicz K, Pragman AA, Kim HB, Hertz M, Wendt C, Isaacson RE. 2012. Longitudinal analysis of the lung microbiome in lung transplantation. FEMS Microbiol. Lett. 339:57-65
115. Charlson ES, Diamond JM, Bittinger K, Fitzgerald AS, Yadav A, et al. 2012. Lung-enriched organisms and aberrant bacterial and fungal respiratory microbiota after lung transplant. Am. J. Respir. Crit. Care Med. 186:536-45
116. Willner DL, Hugenholtz P, Yerkovich ST,Tan ME,Daly JN, et al. 2013. Re-establishment of recipientassociated microbiota in the lung allograft is linked to reduced risk of bronchiolitis obliterans syndrome. Am. J. Respir. Crit. Care Med. 187:640-47
117. Scales BS, Dickson RP, LiPuma JJ, Huffnagle GB. 2014. Microbiology, genomics, and clinical significance of the Pseudomonas fluorescens species complex, an unappreciated colonizer of humans. Clin. Microbiol. Rev. 27:927-48
118. Shulgina L, Cahn AP, Chilvers ER, Parfrey H, Clark AB, et al. 2013. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial. Thorax 68:155-62
119. Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. 2012. Prednisone, azathioprine, and Nacetylcysteine for pulmonary fibrosis. N. Engl. J. Med. 366:1968-77
120. Han MK, Zhou Y, Murray S, Tayob N, Noth I, et al. 2014. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir. Med. 2:548-56
121. Molyneaux PL, Cox MJ, Willis-Owen SA, Mallia P, Russell KE, et al. 2014. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 190:906-13
122. Flaherty KR, Andrei AC, Murray S, Fraley C, Colby TV, et al. 2006. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am. J. Respir. Crit. Care Med. 174:803-9
123. Peljto AL, Zhang Y, Fingerlin TE, Ma SF, Garcia JG, et al. 2013. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA 309:2232-39
124. Iwai S, Huang D, Fong S, Jarlsberg LG, Worodria W, et al. 2014. The lung microbiome of Ugandan HIV-infected pneumonia patients is compositionally and functionally distinct from that of San Franciscan patients. PLOS ONE 9:e95726
125. Toma I, Siegel MO,Keiser J, Yakovleva A, Kim A, et al. 2014. Single-molecule long-read 16S sequencing to characterize the lung microbiome from mechanically ventilated patients with suspected pneumonia. J. Clin. Microbiol. 52:3913-21
126. Lyte M, Ernst S. 1992. Catecholamine induced growth of gram negative bacteria. Life Sci. 50:203-12
127. Dickson RP, Erb-Downward JR, Prescott HC, Martinez FJ, Curtis JL, et al. 2015. Intraalveolar catecholamines and the human lung microbiome. Am. J. Respir. Crit. Care Med. 192:257-59
128. Casadevall A, Pirofski LA. 2003. The damage-response framework of microbial pathogenesis. Nat. Rev. Microbiol. 1:17-24
129. Carmody LA, Zhao J, Schloss PD, Petrosino JF, Murray S, et al. 2013. Changes in cystic fibrosis airway microbiota at pulmonary exacerbation. Ann. Am. Thorac. Soc. 10:179-87
130. Huang YJ, Sethi S, Murphy T, Nariya S, Boushey HA, Lynch SV. 2014. Airway microbiome dynamics in exacerbations of chronic obstructive pulmonary disease. J. Clin. Microbiol. 52:2813-23
131. Millares L, Ferrari R, Gallego M, Garcia-NunezM, Pérez-Brocal V, et al. 2014. Bronchial microbiome of severeCOPDpatients colonised by Pseudomonas aeruginosa. Eur. J. Clin.Microbiol. Infect. Dis. 33:1101-11
132. Price KE,HamptonTH,Gifford AH,Dolben EL, Hogan DA, et al. 2013. Unique microbial communities persist in individual cystic fibrosis patients throughout a clinical exacerbation. Microbiome 1:27
133. Stressmann FA, Rogers GB, Marsh P, Lilley AK, Daniels TW, et al. 2011. Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation? J. Cyst. Fibros. 10:357-65
134. Page SE. 2010. Diversity and Complexity. Princeton, NJ: Princeton Univ. Press
135. Holland JH. 2006. Studying complex adaptive systems. J. Syst. Sci. Complex. 19:1-8